The in vivo study by Mercatelli et al. also confirmed that miR-221/222 inhibition could lead to the upregulation of p27 and reduce the tumor growth of pre-established prostate carcinoma xenografts, thereby indicating the therapeutic potential of miR-221/222 in prostate cancer (31). Here, CDKN1B is linked to prostate carcinoma.